Lozap, 12,5mg 30 pcs.

An antihypertensive drug. Specific angiotensin II receptor antagonist (AT₁ subtype). Does not inhibit kininase II, the enzyme that catalyzes the conversion reaction of angiotensin I to angiotensin II. Reduces RPS, blood concentrations of adrenaline and aldosterone, BP, pressure in the small circulatory circle; reduces post-load, has a diuretic effect. Prevents the development of myocardial hypertrophy, increases exercise tolerance in patients with chronic heart failure. Losartan does not inhibit ACE-kininase II and therefore does not interfere with bradykinin degradation, so bradykinin-mediated side effects (e.g., angioedema) are quite rare.

In patients with arterial hypertension without concomitant diabetes mellitus with proteinuria (greater than 2 g/day), use of the drug significantly reduces proteinuria, albumin and immunoglobulin G excretion.

Stabilizes plasma urea levels. It does not affect autonomic reflexes and has no long-term effect on plasma concentration of norepinephrine. Losartan in dose up to 150 mg/day has no effect on serum levels of triglycerides, total cholesterol and HDL cholesterol in patients with arterial hypertension. At the same dose, losartan has no effect on fasting blood glucose levels.

The hypotensive effect (decrease in systolic and diastolic BP) is maximal after 6 hours after single oral administration and then gradually decreases during 24 hours.

The maximum hypotensive effect develops 3-6 weeks after starting the drug.

Indications

Active ingredient

Composition

Active ingredient:

Potassium losartan 12.5 mg;

Associates:

Microcrystalline cellulose,

Mannitol,

Crospovidone,

How to take, the dosage

Ingestion, regardless of meals. Frequency of administration – once a day.

In case of arterial hypertension, the average daily dose is 50 mg. In some cases, to achieve a greater effect, the dose is increased to 100 mg in 2 doses or once a day.

The starting dose for patients with heart failure is 12.5 mg once daily. Typically, the dose is increased at weekly intervals (i.e., 12.5 mg/day, 25 mg/day, and 50 mg/day) to an average maintenance dose of 50 mg once daily, depending on patient tolerance.

When the drug is administered to patients receiving high-dose diuretics, the starting dose of Lozap should be reduced to 25 mg once daily.

There is no need to adjust the dose in elderly patients or patients with impaired renal function, including patients on hemodialysis.

Patients with impaired liver function should be prescribed lower doses of Lozap.

In elderly patients as well as in patients with impaired renal function, including patients on dialysis, there is no need to adjust the initial dose.

Interaction

Special Instructions

Correction of dehydration should be performed before prescribing Lozap or treatment should be started with a lower dose of the drug.

The drugs affecting the renin-angiotensin system may increase blood urea and serum creatinine concentrations in patients with bilateral renal stenosis or arterial stenosis of the single kidney. Blood potassium concentration should be regularly monitored during treatment, especially in elderly patients with impaired renal function.

Contraindications

Side effects

Overdose

Pregnancy use

Similarities